Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sleep Cycle AB (publ) (SLEEP.ST)
Gothenburg, SE
Founded in 2001 and headquartered in Gothenburg, Sweden, Sleep Cycle AB (publ) specializes in providing applications for sleep monitoring. The company also engineers various devices designed to track both sleep and general health. Its flagship offering is the "Sleep Cycle" application, an intelligent solution that autonomously records and analyzes user sleep patterns.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41% | +57.96% | +38.29% | +56.94% | +7.56% | -10.37% | -20.66% | -27.33% | -69.67% | -69.67% | -69.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Software - Application: +13.0%-5.2% Q1'26: -15.0% (vs Q1'25)
-
EPS growth Software - Application: +28.6%-15.2% Q1'26: -60.3% (vs Q1'25)
-
FCF margin FCF growth · Software - Application: +45.3%+21.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Software - Application: +9.4%+27.3% ★ Q1'26: +13.5% (vs Q1'25)
-
ROIC Software - Application: +7.5%— Q1'26: -71.6% (vs Q1'25)
-
Share dilution Software - Application: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Software - Application: -1.16×0.10× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
182.94M
est: 183.50M (-0.3%)
|
213.27M
est: 213.14M (+0.1%)
|
236.15M
est: 250.93M (-5.9%)
|
261.53M
est: 262.43M (-0.3%)
|
247.88M
est: 251.00M (-1.2%)
|
233.38M
230.92M – 235.84M
-7.0% YoY
|
265.97M
265.87M – 266.07M
+14.0% YoY
|
297.70M
297.55M – 297.85M
+11.9% YoY
|
| EBITDA |
12.37M
est: 45.90M (-73.0%)
|
46.27M
est: 53.31M (-13.2%)
|
64.05M
est: 128.66M (-50.2%)
|
88.45M
est: 134.56M (-34.3%)
|
73.62M
est: 128.70M (-42.8%)
|
119.67M
118.40M – 120.93M
-7.0% YoY
|
136.37M
136.32M – 136.43M
+14.0% YoY
|
152.64M
152.57M – 152.72M
+11.9% YoY
|
| EBIT |
10.33M
est: 42.84M (-75.9%)
|
42.96M
est: 49.76M (-13.7%)
|
59.40M
est: 119.63M (-50.3%)
|
79.83M
est: 125.11M (-36.2%)
|
67.54M
est: 119.66M (-43.6%)
|
111.26M
110.09M – 112.43M
-7.0% YoY
|
126.80M
126.75M – 126.85M
+14.0% YoY
|
141.92M
141.85M – 142.00M
+11.9% YoY
|
| Net Income |
8.11M
est: 24.86M (-67.4%)
|
33.94M
est: 32.04M (+5.9%)
|
46.14M
|
62.64M
est: 64.69M (-3.2%)
|
53.21M
est: 53.74M (-1.0%)
|
33.36M
33.14M – 33.57M
-37.9% YoY
|
43.60M
41.52M – 45.67M
+30.7% YoY
|
32.44M
32.23M – 32.66M
-25.6% YoY
|
| SGA |
85.52M
est: 47.20M (+81.2%)
|
57.74M
est: 54.83M (+5.3%)
|
32.55M
est: 65.36M (-50.2%)
|
57.86M
est: 68.35M (-15.3%)
|
50.82M
est: 65.38M (-22.3%)
|
60.79M
60.15M – 61.43M
-7.0% YoY
|
69.28M
69.25M – 69.30M
+14.0% YoY
|
77.54M
77.50M – 77.58M
+11.9% YoY
|
| EPS |
0.43
est: 1.23 (-64.9%)
|
1.72
est: 1.58 (+8.9%)
|
2.28
|
3.09
est: 3.19 (-3.1%)
|
2.62
est: 2.65 (-1.1%)
|
1.65
1.63 – 1.66
-37.9% YoY
|
2.15
2.05 – 2.25
+30.7% YoY
|
1.60
1.59 – 1.61
-25.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erik Jivmark | Chief Executive Officer | 5M | male |
| Joanna Widestrand | Head of Quality & Compliance for Medical Device | — | female |
| Malin Johansson | Head of Life Science Partnerships | — | — |
| Mikael Kageback | Chief Technology Officer | — | male |
| Mike Gradisar | Head of Sleep Science | — | — |
| Peter Alsterberg | Chief Commercial Officer | — | male |
| Elisabeth Hedman | Chief Financial Officer & Head of Investor Relations | — | female |
| Petter Hoglander | Chief Product Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLEEP.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
